Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
October 2025
The hormone therapy market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. This growth is driven by emerging trends and strong demand across key sectors.
The hormone therapy market is primarily driven by the increasing prevalence of hormone-related disorders and the growing geriatric population. Government organizations launch initiatives to create awareness about screening and early diagnosis of chronic disorders. Researchers also receive funding to conduct research activities and develop novel hormone therapies. Artificial intelligence (AI) and machine learning (ML) algorithms facilitate the development of more personalized treatment. Growing research activities present future opportunities for market growth.
The hormone therapy market is experiencing robust growth, driven by aging populations, rising prevalence of hormone-related disorders, advancements in bioidentical hormones, expanding applications in oncology, and growing awareness of gender health and wellness. It refers to the range of pharmaceutical products and treatment regimens involving natural or synthetic hormones to restore or regulate hormonal balance in patients. It includes therapies for menopause, andropause, thyroid disorders, cancer management (e.g., breast and prostate), growth hormone deficiencies, and gender-affirming care.
AI can transform hormone therapy by enabling healthcare professionals to predict patients who are at high risk of developing hormone-related disorders. AI-based sensors also aid in monitoring hormonal levels in humans, allowing healthcare professionals to prescribe personalized medicines. AI assists researchers in developing novel hormone therapy products tailored to patients' specific conditions. AI and ML can analyze vast amounts of patient data and predict therapeutic outcomes.
LG Chem recently developed its own AI model to predict how much a child will grow in the first year of growth hormone treatment. The model was based on four ML algorithms, such as TabNet, XGBoost, LightGBM, and CatBoost.
| Region | Active, Not Recruiting | Recruiting |
| Global | 460 | 901 |
| United States | 274 | 351 |
| Canada | 90 | 62 |
| China | 72 | 211 |
| Europe | 144 | 210 |
By therapy type, the cancer hormone therapy segment held a dominant presence in the market in 2024, due to the rising prevalence of cancer and the availability of established treatment protocols. Different types of cancer require different hormones for their treatment. For instance, breast cancer is treated with estrogen and progesterone, while prostate cancer is treated with androgens. Hormone therapy eliminates the access of hormones to cancer cells, combating cell growth.
By therapy type, the androgen replacement therapy segment is expected to grow at the fastest CAGR in the market during the forecast period. Androgen replacement therapy (ART) involves the use of testosterone and DHEA in men with hypogonadism and prostate cancer. ART can help reverse the effects of hypogonadism. Several studies have demonstrated the role of testosterone in improving sexual function, vitality, and energy. The availability of different formulations, such as topical gel, transdermal patch, and buccal system, enhances patient convenience.
By hormone source, the synthetic hormones segment held the largest revenue share of the market in 2024, due to widespread availability and cost-effectiveness. Synthetic hormones are artificial compounds, such as synthetic estrogens and glucocorticoids, that are used as contraceptives, HRT, and anti-inflammatory therapies. They may have a similar chemical structure, but not exactly the same as natural hormones. They are found in products that claim to enhance or diminish the effects of hormones.
By hormone source, the bioidentical/natural hormones segment is expected to grow with the highest CAGR in the market during the studied years. Bioidentical hormones are derived from plants that are structurally identical to the body’s natural hormones. They are used in people who experience symptoms of low or unbalanced hormones, i.e., perimenopause or menopause. They are gaining popularity in developed markets due to perceived safety and customization. Additionally, they are safer, more effective, and provide personalized treatment.
By route of administration, the oral segment contributed the biggest revenue share of the market in 2024, due to the ease of administration and cost-effectiveness. Oral contraceptives are the most prescribed hormone therapy for females. The oral route, such as pills, tablets, and capsules, improves medication adherence. Tablets can facilitate either immediate release or sustained release, providing enhanced patient care.
By route of administration, the transdermal segment is expected to expand rapidly in the market in the coming years. The transdermal route is increasingly preferred due to reduced side effects and growing adoption among menopausal and gender-affirming care patients. It provides targeted therapy, as the hormone is directly administered into body fluids. It eliminates first-pass metabolism, reducing systemic side effects.
By application/indication, the menopause & andropause management segment led the market in 2024, due to the increasing number of people undergoing menopause & andropause. This is because of the growing geriatric population and sedentary lifestyles. Hormonal imbalance after menopause & andropause can cause uncomfortable physical and emotional symptoms. This necessitates healthcare professionals to provide treatment that alleviates symptoms of menopause. It is estimated that the population of menopausal and post-menopausal women is projected to rise to 1.2 million by 2030.
By application/indication, the oncology segment is expected to witness the fastest growth in the market over the forecast period. The rising prevalence of hormone-sensitive cancers augments the segment’s growth. The American Cancer Society estimated that over 2 million new cancer cases will be reported in 2025 in the U.S. The increasing demand for precision medicines enables researchers to develop innovative hormone therapies. Hormone therapy prevents cancer cells from receiving signals to proliferate.
By end-user, the hospitals & specialty clinics segment accounted for the highest revenue share of the market in 2024, due to the availability of state-of-the-art infrastructure and suitable capital investment. Hospitals & specialty clinics possess skilled professionals who provide multidisciplinary expertise and personalized care to patients. They adopt advanced treatment based on patients’ conditions. They are also part of clinical trials, benefiting patients with innovative therapies before market approval.
By end-user, the retail & online pharmacies segment is expected to show the fastest growth in the forecast period. Retail & online pharmacies are easily accessible to a large patient base. Retail pharmacies offer advantages, including relevant expertise and 24/7 services. On the other hand, online pharmacies offer special discounts, free home delivery, and virtual consultations. The rapid adoption of telehealth services favors the segment’s growth.
North America dominated the global market in 2024. The availability of state-of-the-art healthcare infrastructure, favorable regulatory policies, and the early adoption of hormone therapies are major growth factors for the market in North America. The presence of key players and increasing collaborations among key players facilitate the development of hormone therapy. The growing adoption of advanced technologies also contributes to market growth.
The Food and Drug Administration (FDA) regulates the approval of hormone therapy in the U.S. Key players, such as Pfizer, Inc., Eli Lilly and Company, and AbbVie, Inc., are the major contributors to the market in the U.S. According to the American Thyroid Association, an estimated 20 million Americans have some form of thyroid disease.
Recent studies have demonstrated that 1 in 10 Canadians suffers from thyroid issues. The Canadian government and British Columbia collaborated to make essential and preventive medications more accessible and more affordable for Canadians. The collaboration intends to implement universal, single-payer, first-dollar coverage for a range of contraception and diabetes medications.
Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period. The rising prevalence of hormone-related disorders, the growing geriatric population, and the increasing population size bolster market growth. The increasing healthcare expenditure and favorable reimbursement policies potentiate healthcare access to a wider population. Government organizations encourage patients to undergo screening and early diagnosis of hormonal disorders.
A recent study found that the overall prevalence of menopausal symptoms in Chinese women aged 40-60 years was 46.3%. Insomnia (50%), fatigue (48.2%), and nervousness (46.9%) were the most common symptoms. In July 2024, Astellas Pharma, Inc. announced that the National Medical Products Administration (NMPA) approved XTANDI (enzalutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).
The current research activities focus on developing personalized hormonal therapies, along with individualized dosing and delivery methods.
Key Players: Abbott, Hanmi Science, Eli Lilly and Company, and Besins Healthcare
Hormone therapy undergoes clinical trials to assess its safety and efficacy in humans. It is later approved by regulatory agencies like the FDA, NMPA, and EMA.
Key Players: Regor Pharmaceuticals, Inc., GBG Forschungs GmbH, and Novartis AG
Patient support & services refers to providing a patient-centered approach, including medical monitoring, personalized care, and extensive education.
Hormone therapy finds immense potential in treating hormone-related disorders by guiding hormones to perform in a particular way. Several studies have proven a better life expectancy for patients with long-term hormonal therapy. According to our analysis, end-users focus on the significance of hormone therapy with novel delivery systems and personalized treatment. Moreover, the increasing number of clinical trials is a result of the growing demand for targeted treatments.
By Therapy Type
By Hormone Source
By Application/Indication
By End-User
By Region
October 2025
October 2025
October 2025
September 2025